How many billions is enough? Prioritizing profits over patients with cystic fibrosis

被引：11
作者：
McGarry, Meghan E. [1 ,6 ]
Gibb, Elizabeth R. [1 ]
Laguna, Theresa A. [2 ]
O'Sullivan, Brian P. [3 ]
Sawicki, Gregory S. [4 ]
Zobell, Jeffery T. [5 ]
机构：
[1] Univ Calif San Francisco, Dept Pediat, Div Pediat Pulm Med, San Francisco, CA USA
[2] Northwestern Univ, Dept Pediat, Div Pulm Med, Feinberg Sch Med, Chicago, IL USA
[3] Dartmouth Coll, Dept Pediat, Div Pediat Pulmonol, Geisel Sch Med, Hanover, NH USA
[4] Harvard Med Sch, Dept Pediat, Div Pulm Med, Boston, MA USA
[5] Univ Utah, Dept Pharmacotherapy, Salt Lake City, UT USA
[6] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
PEDIATRIC PULMONOLOGY | 2023年 / 58卷 / 05期
基金：
美国国家卫生研究院;
关键词：
cystic fibrosis; ethics; personalized medicine; pharmacotherapy;
D O I：
10.1002/ppul.26335
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
引用
收藏
页码：1595 / 1597
页数：3
相关论文
共 8 条
  • [1] Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease
    Burgel, Pierre-Regis
    Durieu, Isabelle
    Chiron, Raphael
    Ramel, Sophie
    Danner-Boucher, Isabelle
    Prevotat, Anne
    Grenet, Dominique
    Marguet, Christophe
    Reynaud-Gaubert, Martine
    Macey, Julie
    Mely, Laurent
    Fenton, Annlyse
    Quetant, Sebastien
    Lemonnier, Lydie
    Paillasseur, Jean-Louis
    Da Silva, Jennifer
    Martin, Clemence
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 204 (01) : 64 - 73
  • [2] Current prices versus minimum costs of production for CFTR modulators
    Guo, Jonathan
    Wang, Junzheng
    Zhang, Jingchun
    Fortunak, Joseph
    Hill, Andrew
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2022, 21 (05) : 866 - 872
  • [3] Pregnancy among cystic fibrosis women in the era of CFTR modulators
    Heltshe, Sonya L.
    Godfrey, Emily M.
    Josephy, Tatiana
    Aitken, Moira L.
    Taylor-Cousar, Jennifer L.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2017, 16 (06) : 687 - 694
  • [4] Left behind: The potential impact of CFTR modulators on racial and ethnic disparities in cystic fibrosis
    McGarry, Meghan E.
    Gibb, Elizabeth R.
    Oates, Gabriela R.
    Schechter, Michael S.
    [J]. PAEDIATRIC RESPIRATORY REVIEWS, 2022, 42 : 35 - 42
  • [5] Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
    Middleton, P. G.
    Mall, M. A.
    Drevinek, P.
    Lands, L. C.
    McKone, E. F.
    Polineni, D.
    Ramsey, B. W.
    Taylor-Cousar, J. L.
    Tullis, E.
    Vermeulen, F.
    Marigowda, G.
    Mckee, C. M.
    Moskowitz, S. M.
    Nair, N.
    Savage, J.
    Simard, C.
    Tian, S.
    Waltz, D.
    Xuan, F.
    Rowe, S. M.
    Jain, R.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (19) : 1809 - 1819
  • [6] Seyoum S., 2020, COST COVERAGE UNDERU
  • [7] The effectiveness and value of novel treatments for cystic fibrosis A summary from the Institute for Clinical and Economic Review's California Technology Assessment Forum
    Tice, Jeffrey A.
    Kuntz, Karen M.
    Wherry, Kael
    Seidner, Matt
    Rind, David M.
    Pearson, Steven D.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (02) : 276 - 280
  • [8] Vertex Pharmaceuticals, 2022, VERT REP 3 QUART 202
1